| Literature DB >> 32150591 |
Saori Oku1,2, Toru Takeshita1,3, Toshiko Futatsuki2, Shinya Kageyama1, Mikari Asakawa1, Yasuo Mori4, Toshihiro Miyamoto4, Jun Hata5,6, Toshiharu Ninomiya5,6, Haruhiko Kashiwazaki2, Yoshihisa Yamashita1.
Abstract
Disruption of the intestinal microbiota caused by intensive chemotherapy, irradiation and antibiotics can result in development of severe gut graft-versus-host disease and infectious complications, leading to poorer outcomes among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Although the oral cavity is also densely colonized by indigenous microorganisms, the bacterial composition in allo-HSCT recipients remains unclear. We determined the tongue microbiota composition of 45 patients with hematological disorders on the day of transplantation and compared them to 164 community-dwelling adults. The V1-V2 regions of the 16S rRNA gene sequences demonstrated that the allo-HSCT recipients had less diverse and distinct microbiota from that of community-dwelling adults. The full-length 16S rRNA gene sequences identified 146 bacterial taxa in the microbiota of allo-HSCT recipients, of which 34 bacterial taxa did not correspond to bacteria primarily inhabiting the oral cavity deposited in the expanded Human Oral Microbiome Database. Notably, the detection of Staphylococcus haemolyticus and/or Ralstonia pickettii was significantly associated with a higher risk of mortality during the follow-up period. These results demonstrate that the oral cavity of allo-HSCT recipients is colonized by a disrupted microbiota on the day of transplantation and suggest that detection of specific nonindigenous taxa could be a predictor of transplant outcome.Entities:
Year: 2020 PMID: 32150591 PMCID: PMC7082065 DOI: 10.1371/journal.ppat.1008348
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Baseline characteristics of the study population.
| No. of patients | |
|---|---|
| Parameter | (n = 45) |
| Median age, yr (range) | 53 (36–69) |
| Sex | |
| Female/Male | 19/26 |
| Underlying disease | |
| Acute myelogenous leukemia | 23 |
| Malignant lymphoma | 10 |
| Acute lymphoblastic leukemia | 5 |
| Myelodysplastic syndrome | 5 |
| Primary myelofibrosis | 1 |
| Aplastic anemia | 1 |
| Risk status at transplantation | |
| Standard/High | 22/23 |
| Conditioning regimen | |
| Myeloablative/Reduced intensity | 20/25 |
| Total body irradiation | |
| None | 10 |
| Low-dose/High-dose | 21/14 |
| Graft source | |
| Bone marrow | 21 |
| Peripheral blood | 20 |
| Cord blood | 4 |
| HLA parity | |
| Matched/Mismatched | 24/21 |
| Antibiotic use during conditioning | |
| Prophylactic/Treatment use | 19/26 |
| GvHD prophylaxis | |
| CIs+sMTX | 32 |
| CIs+MMF±PTCy | 9 |
| Others | 4 |
| Prior transplantation | |
| Yes/No | 6/39 |
| Median number of teeth (range) | 27 (5–32) |
| Bacteremia until day+100 | |
| Yes/No | 12/33 |
| Oral mucositis | |
| Yes/No | 28/17 |
| Grade 2 to 4 | 25 |
| Grade 3 to 4 | 15 |
| Acute GvHD | |
| Yes/No | 25/20 |
| Grade II to IV | 15 |
| Grade III to IV | 4 |
Abbreviation: GvHD, graft-versus host disease, CIs, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide
Fig 1Unweighted UniFrac plot of microbiota composition between community-dwelling adults and allo-HSCT patients.
The ellipses cover 67% of the samples belonging to each sample type.
Fig 2Relative abundances of predominant bacterial genera in the tongue microbiota of community-dwelling adults and allo-HSCT patients.
Only 17 bacterial genera commonly (>98%) present in community-dwelling adults are shown. *P <0.05 in a Wilcoxon rank-sum test followed by P value adjustment for multiple comparison.
Alpha diversity indices of the tongue microbiota of 164 community-dwelling adults and 45 allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients on transplantation date in V1-V2 regions of 16S rRNA gene sequencing analysis.
| Community-dwelling adults | allo-HSCT recipients | ||
|---|---|---|---|
| Number of OTU | 90.9 ± 18.3 | 41.1 ± 15.6 | <0.001 |
| Phylogenetic diversity | 6.9 ± 1.1 | 4.0 ± 1.1 | <0.001 |
| Shannon diversity index | 3.2 ± 0.3 | 2.1 ± 0.6 | <0.001 |
Values with errors are mean ±SD.
aWilcoxon rank-sum test.
Nonindigenous bacteria identified from the tongue microbiota found in allo-HSCT recipients on the transplantation date in full-length 16S rRNA gene analysis.
| No. of subjects with each taxon | Relative abundance (%) | ||
|---|---|---|---|
| Bacterial taxa | Mean | Max | |
| 13 | 0.06±0.18 | 1.06 | |
| 8 | 4.96±19.29 | 95.41 | |
| uncultured organism (HQ813300) | 8 | 0.14±0.57 | 3.75 |
| 6 | 1.09±6.33 | 42.49 | |
| 3 | 0.14±0.91 | 6.14 | |
| 2 | 0.49±2.84 | 18.91 | |
| uncultured | 2 | 0.06±0.38 | 2.53 |
| 2 | 0.05±0.34 | 2.28 | |
| 2 | 0.03±0.14 | 0.70 | |
| 2 | 0.01±0.09 | 0.57 | |
| 2 | 0.01±0.07 | 0.50 | |
| uncultured organism (HQ771651) | 2 | 0.01±0.07 | 0.44 |
| 2 | 0.01±0.06 | 0.39 | |
| uncultured bacterium (GQ129984) | 2 | 0.01±0.03 | 0.15 |
| 2 | 0±0.02 | 0.11 | |
| uncultured bacterium (EU937980) | 1 | 0.17±1.13 | 7.61 |
| 1 | 0.06±0.41 | 2.74 | |
| uncultured | 1 | 0.04±0.27 | 1.84 |
| 1 | 0.02±0.16 | 1.08 | |
| 1 | 0.02±0.14 | 0.96 | |
| uncultured bacterium (HE681344) | 1 | 0.02±0.10 | 0.69 |
| 1 | 0.01±0.08 | 0.52 | |
| 1 | 0.01±0.04 | 0.30 | |
| uncultured | 1 | 0.01±0.04 | 0.25 |
| 1 | 0±0.03 | 0.21 | |
| 1 | 0±0.02 | 0.17 | |
| Genus | 1 | 0±0.02 | 0.17 |
| Genus | 1 | 0±0.03 | 0.17 |
| 1 | 0±0.02 | 0.14 | |
| uncultured bacterium (AM277332) | 1 | 0±0.02 | 0.13 |
| 1 | 0±0.02 | 0.11 | |
| 1 | 0±0.01 | 0.10 | |
| 1 | 0±0.01 | 0.09 | |
| 1 | 0±0.01 | 0.04 | |
Values with errors are mean ±SD.
aTaxon ID in expanded Human Oral Microbiome database (triple digits) or GenBank number is given in parentheses following bacterial name.
Fig 3Survival plots of the patients with detection or no detection of Staphylococcus haemolyticus and Ralstonia pickettii on the tongue generated by the Kaplan–Meier method.
Significant differences were determined using a log-rank test.
Univariate and multivariate associations of the detection of Staphylococcus haemolyticus and/or Ralstonia pickettii with the high risk of mortality at the follow-up period in Cox proportional hazard regression models.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | |||||
| HR (95% CI) | aHR (95% CI) | aHR (95% CI) | ||||
| Detection of either/both of the two taxa | 3.5 (1.4–8.6) | .006 | 2.5 (1.0–6.4) | .04 | 3.1 (1.0–9.2) | .03 |
| Age | 1.0 (0.9–1.0) | .26 | ||||
| Underlying disease (leukemia vs other) | 1.2 (0.4–3.2) | .66 | ||||
| Risk status at transplantation | 5.1 (1.8–14.2) | .001 | 4.1 (1.4–11.7) | .008 | ||
| Conditioning regimens | ||||||
| Myeloablative | (reference) | |||||
| Reduced intensity | 1.3 (0.5–3.2) | .54 | ||||
| Total body irradiation | ||||||
| None | (reference) | |||||
| Low dose | 1.2 (0.2–2.1) | .62 | ||||
| High dose | 1.8 (0.1–1.7) | .30 | ||||
| Antibiotics use during conditioning | ||||||
| Prophylactic use | (reference) | |||||
| Additional use for treatment | 2.3 (0.8–6.5) | .09 | 1.2 (0.3–4.2) | .70 | ||
| Graft source | ||||||
| Peripheral blood | (reference) | |||||
| Bone marrow | 1.3 (0.5–3.4) | .53 | ||||
| Cord blood | 1.1 (0.2–5.4) | .86 | ||||
| HLA parity | ||||||
| Matched | (reference) | |||||
| Mismatched | 1.3 (0.5–3.1) | .53 | ||||
| GvHD prophylaxis | ||||||
| CIs+sMTX | (reference) | |||||
| CIs+MMF±PTCy | 1.4 (0.5–4.0) | .47 | ||||
| Others | 1.5 (0.3–7.0) | .54 |
Abbreviation: HR, hazard ratio; aHR, adjusted hazard ratio; GvHD, graft-versus host disease; CIs, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide.
Relationship between the detection of Staphylococcus haemolyticus and/or Ralstonia pickettii and the baseline characteristics of the recipients.
| Either/both of the two taxa | |||
|---|---|---|---|
| Detected | Not detected | ||
| (n = 17) | (n = 28) | ||
| Age (Mean ±SD) | 54±10 | 51±10 | 0.46 |
| No. (%) of female | 9 (52.9) | 10 (35.7) | 0.35 |
| Underlying disease | 0.73 | ||
| Acute myelogenous leukemia | 8 (47.0) | 15 (53.5) | |
| Malignant lymphoma | 5 (29.4) | 5 (17.8) | |
| Acute lymphoblastic leukemia | 1 (5.8) | 4 (14.2) | |
| Myelodysplastic syndrome | 2 (11.7) | 3 (10.7) | |
| Primary myelofibrosis | 0 (0) | 1 (3.5) | |
| Aplastic anemia | 1 (5.8) | 0 (0) | |
| Prior transplantation | 2 (11.7) | 4 (14.2) | 1.00 |
| Risk status at transplantation | 0.06 | ||
| Standard | 5 (29.4) | 17 (60.7) | |
| High | 12 (70.5) | 11 (39.2) | |
| Conditioning regimens | 0.37 | ||
| Myeloablative | 6 (35.2) | 14 (50.0) | |
| Reduced intensity | 11 (64.7) | 14 (50.0) | |
| Antibiotic use during conditioning | 0.001 | ||
| Prophylactic use | 2 (11.7) | 17 (60.7) | |
| Additional use for treatment | 15 (88.2) | 11 (39.2) | |
| Total body irradiation | 0.72 | ||
| None | 4 (23.5) | 6 (21.4) | |
| Low dose | 9 (52.9) | 12 (42.8) | |
| High dose | 4 (23.5) | 10 (35.7) | |
| Graft source | 0.07 | ||
| Peripheral blood | 11 (64.7) | 10 (35.7) | |
| Bone marrow | 4 (23.5) | 16 (57.1) | |
| Cord blood | 2 (11.7) | 2 (7.1) | |
| HLA parity | 0.23 | ||
| Matched | 7 (41.1) | 17 (60.7) | |
| Mismatched | 10 (58.8) | 11 (39.2) | |
| GvHD prophylaxis | 0.41 | ||
| CIs+sMTX | 10 (58.8) | 22 (78.5) | |
| CIs+MMF±PTCy | 5 (29.4) | 4 (14.2) | |
| Others | 2 (11.7) | 2 (7.1) | |
aStudent’s t-test.
bFisher’s exact test.
Abbreviation: GvHD, graft-versus host disease; CIs, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide.